Ziopharm Oncology Inc (NASDAQ:ZIOP) Shorts Strengthened By 0.09%

June 29, 2018 - By Darrin Badillo

It was showed an increase on Ziopharm Oncology Inc (NASDAQ:ZIOP)’s shorted shares with 0.09%. In June was announced ZIOP’s total 35.65M shorted shares by FINRA. The up change of 0.09% from 35.62M shares was reported. Former ZIOP’s position will need 48 days to restore. It has 751,200 average volume. Ziopharm Oncology Inc float short is 32.78%.

The stock decreased 1.95% or $0.06 during the last trading session, touching $3.01.ZIOPHARM Oncology, Inc. has volume of 572,478 shares. Since June 29, 2017 ZIOP has declined 31.35% and is downtrending. The stock underperformed the S&P 500 by 43.92%.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is valued at $424.01 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Last it reported negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

A total of 2 analysts rate Ziopharm Oncology (NASDAQ:ZIOP) as follows: 1 “Buy”, 0 “Hold” and 1 “Sell”. Тherefore 50% are bullish. (NASDAQ:ZIOP) has 3 ratings reports on Jun 29, 2018 according to StockzIntelligence. In Monday, June 18 report JP Morgan downgraded the stock to “Underweight” rating. On Monday, May 14 H.C. Wainwright maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) rating. H.C. Wainwright has “Buy” rating and $5.5000 target. On Monday, March 5 the firm has “Buy” rating by H.C. Wainwright given.

For more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news brought out briefly go to: Seekingalpha.com, Nasdaq.com, Globenewswire.com, Nasdaq.com or Streetinsider.com. The titles are as follows: “Ziopharm down 12% premarket on likely delay in Phase 1 CAR-T study” brought out on June 18, 2018, “Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher” on June 18, 2018, “Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19 …” with a publish date: June 18, 2018, “Investor Expectations to Drive Momentum within ZIOPHARM Oncology, MedEquities Realty Trust, Argan, Churchill …” and the last “Pre-Open Movers 06/18: (PTCT) (CBPO) (RCII) Higher; (CBIO) (ZIOP) (RDFN) Lower (more…)” with publication date: June 18, 2018.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: